Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916631 | 0.80 | NPC1 (0.46) | SMN1; SMN2LMNANPC1 | |
| SCHEMBL2917355 | 0.80 | NPC1 (0.46) | SMN1; SMN2LMNANPC1 | |
| SCHEMBL1114734 | 0.80 | MAPT (0.40) | SMN1; SMN2HTTCYP2C19LTA4HKMT2A | |
| SCHEMBL1975707 | 0.80 | MAPT (0.40) | SMN1; SMN2HTTCYP2C19LTA4HKMT2A | |
| SCHEMBL27440241 | 0.79 | TRPA1 (0.47) | SMN1; SMN2HTTCYP2C19ALDH1A1KMT2A | |
| SCHEMBL14437758 | 0.79 | HTT (0.41) | SMN1; SMN2HTTCYP2C19LTA4HKMT2A | |
| SCHEMBL5549557 | 0.79 | HTT (0.41) | SMN1; SMN2HTTCYP2C19LTA4HKMT2A | |
| SCHEMBL5552489 | 0.79 | HTT (0.41) | SMN1; SMN2HTTCYP2C19LTA4HKMT2A | |
| SCHEMBL11116485 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2HTTCYP2C19ALDH1A1KMT2A | |
| SCHEMBL735424 | 0.77 | LTA4H (0.55) | SMN1; SMN2HTTLTA4HALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-04-14 | — | — | US | disclosed |
| CN-107614501-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | SMN1; SMN2 1801/4885HTT 2473/4885CYP2C19 521/4885 |
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | SMN1; SMN2 1801/4885HTT 2473/4885CYP2C19 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.